DiscoveryBioMed, Inc. (DBM) is a life sciences and biotechnology company, located in Birmingham, AL, formed with the ultimate goal of integrating human cell physiology with the drug discovery critical path. DBM’s founder, Erik Schwiebert, Ph.D., a physiologist by trade, launched the company in October 2007 and closed on seed capital investment with Greer Capital Advisors in November of 2007 (Birmingham Technology Fund). Since then DBM has continued to grow and gain recognition both locally and nationally.
DiscoveryBioMed was awarded a $5,000 preliminary research grant to purchase normal and diseased human lung cells from commercial vendors for critical lead profiling experiments. DBM submitted their NIH Phase 1 proposal in January 2016.
Learn more about DiscoveryBioMed by visiting our blog.